Background
Naltrexone is an opioid antagonist which effectively blocks heroin effects. Since opioid dependence treatment with naltrexone tablets suffers from high dropout rates, several depot injections and implants are under investigation. Sustained-release formulations are claimed to be effective, but a systematic review of the literature is lacking.
Objectives
To evaluate the effectiveness of sustained-release naltrexone for opioid dependence and its adverse effects in different study populations.
Search strategy
The following databases were searched from their inception to November 2007: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, LILACS, PsycINFO, ISI Web of Science, trial database at http://clinicaltrials.gov, available NIDA monographs, CPDD and AAAP conference proceedings. The reference lists of identified studies, published reviews and relevant web sides were searched manually. Study authors and drug companies were contacted to obtain any unpublished material or missing data.
Selection criteria
To evaluate effectiveness only RCTs were included. To evaluate safety, any clinical trial reporting adverse effects was assessed. Treatment condition was extended to include alcohol dependent subjects and healthy volunteers.
Data collection and analysis
Reviewers independently evaluated the reports, rated methodological quality and extracted data. Analyses were performed separately for opioid dependent, alcohol dependent and healthy participants.
Main results
Foe effectiveness, one report met inclusion criteria. Two dosages of naltrexone depot injections (192 and 384 mg) were compared to placebo. High-dose significantly increased days in treatment compared to placebo (WMD 21.00, 95% CI 10.68 to 31.32, p<0.0001). High-dose compared to low-dose significantly increased days in treatment (WMD 12.00, 95% CI 1.69 to 22.31, p=0.02). Number of patients retained in treatment did not show significant differences between groups.
For adverse effects, seventeen reports met inclusion criteria analyses, six were RCTs. Side effects were significantly more frequent in naltrexone depot groups compared to placebo. In alcohol dependent samples only, adverse effects appeared to be significantly more frequent in the low-dose naltrexone depot groups compared to placebo (RR 1.18, 95% CI 1.02 to 1.36, p=0.02). In the opioid dependent sample, group differences were not statistically significant. Reports on systematic assessment of side effects and adverse events were scarce.
Authors' conclusions
There is insufficient evidence to evaluate the effectiveness of sustained-release naltrexone for treatment of opioid dependence. For naltrexone injections, administration site-related adverse effects appear to be frequent, but of moderate intensity and time limited. For a harm-benefit evaluation of naltrexone implants, more data on side effects and adverse events are needed.
P L A I N L A N G U A G E S U M M A R Y
People with opioid dependence require substantial therapeutic effort to keep them drug free. Their use of illicit opioids can be reduced and retention in treatment improved with supervised agonist replacement therapy with methadone, which is a highly addictive drug. Naltrexone is a long-acting, opioid-antagonist that blocks heroin effects. It is used to prevent relapse of both opioid and alcohol dependence. Highly motivated people do best with naltrexone. Most opioid users are sceptical about treatment with naltrexone tablets and many drop out early on. Dropouts can be reduced with supervised tablet taking, offering incentives and using sustained-release naltrexone such as subcutaneous implants or depot injections. There is insufficient evidence from randomised controlled trials to evaluate the effectiveness of sustained-release naltrexone. In the one controlled study that met inclusion criteria, 60 outpatients were randomised to one of three groups that received two sequential depot injections of naltrexone (192 or 384 mg) or placebo injections. The mean dropout time was 48 days with high dose naltrexone compared with 27 days on placebo; an increase in treatment of 21 days (range 11 to 31 days). The lower depot dose gave a lesser benefit. The number retained in treatment at eight weeks did not show a clear difference and ranged from a mean of 68% to 39% of participants in the different groups. 'Wanting heroin' did not differ on naltrexone but 'needing heroin' scored significantly lower with depot naltrexone compared to placebo. The most prominent adverse effects were general symptoms of fatigue and pain at the injection site. Seventeen reports met inclusion criteria for assessing adverse effects. Seven looked specifically at naltrexone implants for treatment of opioid dependence and wound infection, allergic reaction to the implant and number of implants removed. The majority of the trials did not have a control group and systematic assessment of adverse effects was lacking.
B A C K G R O U N D
Opioid dependence is considered a chronic lifelong relapsing disorder, which requires substantial therapeutic efforts to keep patients drug free (McLellan 2000) . The prevalence of opioid dependence is rather low and varies from 0.1 to 1.0 % among adult populations in Europe and the US, but reliable estimates are difficult to obtain (EMCDDA 2006; OAS 2005) .
The currently most effective and well-investigated treatment for opioid dependence is agonist replacement therapy with methadone (Amato 2005; Mattick 2003; van den Brink 2006) . Methadone Maintenance Treatment (MMT) implies supervised intake of a long-acting opioid receptor agonist. MMT reduces illicit opioid use and increases retention in treatment substantially. Despite evidence of its effectiveness, clinicians as well as users may be critical towards long-term prescription of a highly addictive drug. Hence, non-addictive alternatives have been in the focus of research for several decades.
Naltrexone is a long-acting, non-selective opioid-antagonist with highest affinity to mu-opioid receptors (Gonzalez 1988) . A daily ingested dose of 50 mg sufficiently blocks the effect of opioids to prevent relapse. Tolerance to and dependence on naltrexone does not develop (Navaratnam 1994; Rawson 2000) . Oral naltrexone is approved for relapse prevention of alcohol and opioid dependence in several countries. Some trials showed promising results of oral naltrexone maintenance compared to placebo (Guo 2001) , whereas others failed to detect an effect (San 1991) . A Cochrane review did not find enough evidence to unequivocally support the clinical effectiveness of oral naltrexone in the treatment of opioid dependence (Minozzi 2006 ).
An important factor predicting treatment outcome of opioid dependence is treatment retention. Compared to agonist replacement therapy, the majority of opioid users are rather skeptical towards treatment with naltrexone tablets. Hence, maintenance therapy with oral naltrexone suffers from high early dropout rates, which has been counteracted by supervised ingestion of the tablets. Systematic use of incentives in order to externally strengthen patient motivation has been evaluated (Preston 1999). Another important variable to predict treatment outcome is vocational and social stability. Systematically selected and supposedly highly motivated patients seem to do better in oral naltrexone maintenance therapy than unbiased samples (Ginzburg 1984; Cornish 1997) .
From a pharmacological point of view, efforts have been made to improve retention in treatment by administering naltrexone as a subcutaneous implant or depot injection. Development of sustained-release formulations commenced three decades ago (Chiang 1985; Reuning 1976) . Only recently has sustained-release naltrexone become available for evaluation in larger human samples (Comer 2007) . The objective of using sustained-release naltrexone is to secure medication compliance for weeks or even months, thus removing the onus from patients to take naltrexone tablets daily. At least 9 different sustained-release formulations are available. To date, none is approved for opioid dependence treatment in Australia, the EU or the US. Three depot injection formulations are under investigation, providing therapeutic naltrexone blood levels between 1 and 2 ng/ml for approximately 4 weeks: Vivitrol by Alkermes Inc., Depotrex by Biotek Inc. and Naltrel by Elbion. Another approach to provide therapeutic blood levels for several months is to load a biodegradable polylactic based polymer with naltrexone in implant formulations. Several implants are available commercially or through clinical trials: Sherman, Wedgewood, GoMedical (http://www.naltrexane.com/), Cravex (Partecke 2007), Prodetoxone, which is approved for treatment of opioid dependence in Russia (Krupitsky 2007) and a Chinese implant formulation (Moran 2007, see also http://www.1212.hk/). Since treatment with sustained-release naltrexone is hardly or even not reversible for a limited period of time, carefully assessing patients' motivation must be considered essential before treatment start. While results from clinical trials involving several hundred patients have been published, a systematic review of the literature is lacking.
The aim of this review is to evaluate the effectiveness and adverse effects of sustained-release naltrexone formulations used in humans.
O B J E C T I V E S
To evaluate the effect of sustained-release naltrexone for opioid dependence compared to placebo or alternative treatment. To evaluate adverse effects of sustained-release naltrexone formulations currently under investigation in different study populations.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W

Types of studies
For assessment of effectiveness only randomised-controlled clinical trials on sustained-release naltrexone for treatment of opioid dependence were considered. For evaluation of safety and adverse effects prospective controlled and uncontrolled trials, case series and record-linkage studies were considered.
Types of participants
Adults or adolescents with opioid dependence. Studies investigating naltrexone treatment for other conditions were excluded for effectiveness evaluation. For adverse effects evaluation only, any research on healthy participants and any research on treatment for other conditions than opioid dependence was included.
Types of intervention
Any use of sustained-release formulations (i.e. depot or implant) of naltrexone compared to any other pharmacological or psychosocial or no treatment.
• Sustained-release naltrexone versus oral naltrexone
• Sustained-release naltrexone versus placebo
• Sustained-release naltrexone versus agonist replacement therapy
• Sustained-release naltrexone versus psychosocial interventions
• Sustained-release naltrexone versus no treatment Retrieved from literature search, but not predefined in protocol:
• Low-dose versus high-dose sustained-release naltrexone Outcome measures not considered in protocol but retrieved from literature search: (10) Heroin craving
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Drugs and Alcohol Group methods used in reviews.
To identify studies for this review detailed electronic searches for each data base were performed.
Electronic searches:
Electronic searches were performed to identify any RCTs investigating the effect of sustained-release naltrexone and any type of study on side effects and adverse events. The detailed search strategy was developed for MEDLINE but revised appropriately for each database to match vocabulary and syntax rules. No language restrictions were made.
The following databases were searched to identify reports on the effectiveness and adverse effects of sustained-release naltrexone: 1. MEDLINE (January 1966 Detailed search strategies for the other databases are described in additional Table 03 .
Additional searches
Manual searches in reference lists, relevant web sites, the trial registers at http://www.clinicaltrials.gov and http://www.controlled-trials.com, conference abstracts (Annual Meetings of the College on Problems of Drug Dependence (CPDD), Annual Meetings of the American Academy of Addiction Psychiatry (AAAP)) were performed. Triallists and pharmaceutical companies were approached to obtain unpublished results, but contact proved difficult to establish.
M E T H O D S O F T H E R E V I E W
Study selection
Two authors independently assessed potentially relevant studies for inclusion. Any disagreement between the authors was resolved by discussion. If consensus was not achieved, the senior author was consulted. Missing information was sought by contacting study authors.
Assessment of methodological quality
Two authors independently assessed methodological quality of eligible studies. Any disagreement was resolved by consulting the senior author. Methodological quality assessment of all included studies was used to systematically describe possible bias and did not present a threshold for inclusion of trials. Study quality of RCTs was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions criteria (Higgins 2006):
(1) Measures to avoid selection bias Allocation concealment in RCTs: A) Adequate allocation concealment: central randomisation (e.g. allocation by a central office unaware of participant characteristics), pre-numbered or coded identical bottles or containers which are administered serially to participants, drug prepared by the pharmacy, serially numbered, opaque, sealed envelopes, on-site computer system combined with allocations kept in a locked unreadable computer file that can be accessed only after the characteristics of an enrolled participant have been entered, or other description that contained elements convincing of concealment. B) Unclear allocation concealment: when the authors either did not report an allocation concealment approach at all or report an approach that did not fall in the category A or C. C) Inadequate allocation concealment: alternation or reference to case numbers, dates of birth, day of the week. Any procedure that is entirely transparent before allocation, such as an open list of random numbers or other description that contained elements convincing of not concealment D) no allocation concealment used 
Data collection
Two review authors independently extracted data using predefined data extraction forms. Any disagreement was resolved by consensus, if necessary by discussion with a third reviewer.
Data synthesis
Meta-analyses were performed were appropriate for all prespecified outcomes. Individual and pooled relative risks (RR) with 95% confidence intervals (CI) were calculated for dichotomous outcomes, using the fixed-effects model unless studies were heterogeneous, in which case the random-effects model was used. Statistical heterogeneity was assessed by the Chi-squared test, with P < 0.05 indicating heterogeneity. Additionally, I-squared (values from 0 to 100 %, with 0 % indicating no observed heterogeneity) were calculated to assess inconsistency. Weighted mean differences (WMD) with 95% CI were calculated for continuous outcomes. From a clinical perspective, it seemed reasonable to analyse safety outcomes from reports on opioid dependent, alcohol dependent and healthy volunteers separately.
D E S C R I P T I O N O F S T U D I E S
Sixty eight reports of potential interest were identified and assessed, only 1 (Comer 2006) met criteria for inclusion into effectiveness analyses. Seventeen of 68 identified reports were included to evaluate adverse effects of sustained-release naltrexone treatment (including Comer 2006) . In 2 reports the same population was investigated and only the primary publication (Waal 2003) was included. For adverse effects evaluation, unpublished data from 2 reports was retrieved and used (Gölz 2000 , Waal 2003 . A flow chart of the study inclusion process is provided in additional Figure 01 .
Studies excluded from effectiveness and safety analyses
Reasons for exclusion of the remaining 50 reports were: publication was no clinical trial (25 reports), adverse effect data not provided (11 reports), intervention was oral naltrexone (9 reports), publication on pharmacokinetics of a non-recommendable formulation (3 reports), abstract available only (1 report Included studies (a) Study of effectiveness of sustained-release naltrexone for opioid dependence One RCT ,conducted in the USA, met inclusion criteria (Comer 2006) . A depot formulation of sustained-release naltrexone (Depotrex) was investigated among 60 outpatients. Three parallel groups received 2 sequential naltrexone injections of 192 mg or 384 mg, the control group received 2 placebo injections. In addition, all participants were offered manualised relapse prevention therapy. Clinic visits were scheduled twice weekly during the 8 weeks observation period. Primary outcome measures were treatment retention and opioid use assessed by urinalysis. Other illicit drug use, heroin craving, adverse effects, depression and severity of opioid and cocaine use were considered secondary outcomes. All outcome analyses were conducted on the intention-to-treat (ITT) population.
(b) Studies of adverse effects of sustained-release NTX Seventeen reports were included in the adverse effect analyses, 6 were RCTs. (See table characteristics of included studies.)
• Populations
In 10 reports participants were opioid dependent. Two of these reports were restricted to a non-treatment seeking population • Country 2 trials were conducted in Australia, 1 in Germany, 2 in Norway, 1 in Spain, 1 in the UK and 10 in the USA.
• Interventions
The investigated drugs included 3 depot formulations (Alkermes, Biotek, DrugAbuse Sciences) containing 150 to 400 mg of naltrexone and 2 implant formulations (GoMedical, Wedgewood) containing 1000 to approximately 2200 mg of naltrexone. In 10 of 17 reports depot formulations of sustained-release naltrexone were used. The study samples were healthy volunteers, alcohol or opioid dependent patients in 1, 6 and 3 reports, respectively. In the remaining 7 reports on naltrexone implants, all participants were opioid dependent. (See additional Table 02 
Outcome measures
Two categories of adverse effects were assessed in 9 of the 17 reports: possibly naltrexone-related AEs (e.g. headache, nausea) and administration site-related AEs, such as itching, pain, tissue reactions or surgical site revision. In the majority of studies involving opioid dependent populations only administration site-related AEs were reported, however, in the record-linkage study by Tait 2007 mortality during course of treatment was investigated. Most reports on alcohol dependent subjects included assessment of AEs possibly related to both categories: the drug naltrexone and its particular formulation used. The predefined outcome measure time to AE was not assessed in any report.
Studies ongoing
We found six studies ongoing, as soon as results will be available, we will update the results.
M E T H O D O L O G I C A L Q U A L I T Y (See additional Table 01)
Study of effectiveness
In the 1 report included for analyses of effectiveness, the method of allocation concealment was not clearly described (category B). The trial was conducted in a double-blind fashion (category A) and loss to follow up was recorded completely for each treatment arm (category A). It remains unclear whether or not the outcome assessors were blind to which intervention participants had received (category B).
Studies of adverse effects (see table characteristics of included studies)
RCTs: 6 reports 1) Comparison and allocation concealment: In 1 of 6 RCTs an opioid dependent sample was investigated, this report was also included for analyses of effectiveness (Comer 2006) . A detailed description of an adequate method for allocation concealment (category A) was provided by 1 study group (Kranzler 2004) , the other 5 descriptions were rated category B: unclear allocation concealment.
2) Blinding of participant / provider: All 6 RCTs were considered double-blind (category A), i.e. those receiving and providing treatment were blind to the intervention used.
3) Drop out:
In 5 RCTs loss to follow up was completely recorded for each treatment group (category A). The RCT by Dunbar 2006 was rated category B: loss to follow up incompletely recorded. 4) Blinding of the outcome assessor: One of 6 RCTs was considered triple blind: besides participants and treatment staff, researchers assessing outcomes were blind to treatment allocation (Garbutt 2005) . The remaining 5 RCTs were rated category B: unclear if outcome assessor was blind to treatment allocation.
non-RCTs with parallel control group: 2 reports Turncliff 2005 used a matched case-control design to compare liver impaired alcohol dependent patients and healthy controls. This trial was open-lable, loss to follow-up was completely recorded for each group. Tait 2007 retrospectively compared record-linkage data of opioid dependent patients receiving naltrexone implant to patients entering methadone maintenance. Patient data was recorded prospectively by health care staff who was considered blind to treatment condition. Reporting drop-out was not feasible due to record-linkage study design.
non-RCTs without parallel control group: 9 reports Eight of the 9 reports were investigations on opioid dependent samples, only Galloway 2005 investigated an alcohol dependent sample. In 7 reports loss to follow up was completely recorded for treatment groups. In the remaining 2 reports the description of drop-outs was either not done (Carreno 2003) or not feasible due to record-linkage study design (Hulse 2005) .
R E S U L T S
• Effectiveness of sustained-release naltrexone for opioid dependence For the 1 report (Comer 2006 ) that met inclusion criteria for effectiveness studies, the following primary treatment outcomes allowed calculations of effect estimates: (1) Retention in treatment (number of participants in each group completing the 8-week study period) (2) Time to drop out (number of days in treatment) All confidence intervals are 95%, effect estimates are based on intention-to-treat analyses.
(1) Retention in treatment at week 8 was 68.2%, 60.0% and 38.9% of participants in the high dose, low dose and placebo group. There was no statistically significant difference between either dosage of depot naltrexone and placebo with high dose, one study, 40 participants, RR 1.75 (CI 0.92 to 3.34), see comparison 01, outcome 01; and low dose, onestudy, 38 participants, RR 1.54 (CI 0.78 to 3.05), see comparison 01outcome 02. No statistically significant difference was found between groups receiving naltrexone depot, one study, 42 participants, RR 1.14 (CI 0.72 to 1.80), see comparison 01, outcome 03.
(2) Time to drop out was 48, 36 and 27 days in the high dose, low dose and placebo group. Group comparisons were statistically significant between high dose naltrexone depot and placebo, one study, 40 participants, WMD 21.0 (CI 10.68 to 31.32), see comparison 01 outcome 04, and between high and low dose depot, one study, 42 participants, WMD 12.0 (CI 1.69 to 22.31), see comparison 01, outcome 05. There was no statistically significant difference between low dose depot and placebo, one study, 38 participants, WMD 9.0 (CI -3.40 to 21.40), see comparison 01, outcome 06. The comparisons described below were regarded secondary outcomes by Comer 2006. Calculation of effect estimates was not possible with the data provided. (3) heroin craving assessed on visual analogue scales (4) depression / severity of drug use (5) naltrexone blood levels (3) Heroin craving, on visual analogue scales: "Wanting heroin" did not show significant group differences throughout the study. "Needing heroin" was scored significantly lower by the high and low dose naltrexone depot group compared to the placebo group (p<0.001). (4) Depression (HAM-D scale); severity of opioid and cocaine use (CGIS): No significant difference between treatment groups was reported on depression or severity of drug use scores. In regard to depression, all groups scored lower on HAM-D at follow-up than at baseline. (5) Mean plasma levels of naltrexone during the 8 weeks study period ranged from 1.3 to 3.2 ng/ml in the high dose group. In the low dose group mean plasma levels were measured between 0.4 and 1.9 ng/ml. 4 weeks after the first injection plasma trough levels were reached and the naltrexone depot re-administered. Effect analyses for non-RCTs were performed separately from the RCTs. Subgroup analyses were performed seperately for the different populations, i.e. opioid dependent, alcohol dependent and healthy controls.
(1) RCTs High-dose naltrexone depot compared to placebo injection: • Alcohol dependence, 1 RCT by Garbutt 2005: Group differences for number of participants discontinuing the trial due to adverse effects were significant in favour of control, 415 participants, RR 2.12 (CI 1.02 to 3.22), see comparison 02, outcome 07, sub-category 01. No significant differences for reporting injection site pain, 415 participants, RR 1.37 (CI 0.76 to 2.44), see comparison 02, outcome 07, sub-category 02) and for reporting an severe adverse effect (as described above), 415 participants, RR 0.93 (CI 0.40 to 2.15), see comparison 02, outcome 07, sub-category 03.
(2) non-RCTs with parallel control group Liver impaired compared to healthy controls: In the report by Turncliff 2005 the same dose of naltrexone depot (Alkermes Inc. 190 mg) was administered in two non-randomized groups: cases consisting of liver impaired, currently abstinent alcohol dependent patients matched to a control group of healthy volunteers. The relative risk of reporting 1 or more AE was statistically significant in favour of control, 25 participants, RR 3.25 (CI 1.14 to 9.24), see comparison 02, outcome 08. Naltrexone implant compared to methadone maintenance: In Tait 2007 mortality of two non-randomised cohorts of opioid dependent patients treated with naltrexone implants (GoMedical Inc.) or methadone maintenance is described. Of the 341 patients in the naltrexone group, 6 died in the study period between 2001 and 2006, whereas 15 of 553 patients in MMT died during those years. Group differences were not statistically significant with RR 0.65, CI 0.25 to 1.66 (see comparison 02, outcome 09). (3) Adverse effects of sustained-release naltrexone treatment reported in non-RCTs without control group (a) Naltrexone implant (GoMedical Inc., Australia) for treatment of opioid dependence In the report by Waal 2006 a local tissue reaction was evident in 2 of 13 participants, in both cases the sites were surgically revised and the implants removed. According to unpublished data from this trial, possibly naltrexone-related adverse effects were decreasing during the course of the study, for example: irritability was reported by 6 of 12 patients 1 week after treatment start; at week 8 only 2 of 6 subjects reported irritability. Headache and nausea were experienced by 5, respectively 2 of 12 participants 1 week after treatment start. At week 8 none of the 6 patients still in treatment complained about headache or nausea. In the report by Hulse 2005 3 implant removals in 361 treated patients were registered: 1 due to wound infection and 2 on patients' request. No statement on possibly drug-related AEs or number of treatment responsive wound infections was made. 
D I S C U S S I O N
The main result of this review is a negative one: evidence to evaluate effectiveness of sustained-release naltrexone for treatment of opioid dependence is scarce. Only one report met inclusion criteria for analyses of effectiveness (Comer 2006) . The naltrexone depot injection appeared dose-dependently beneficial: more subjects in the high-dose group spent longer time in treatment than subjects in the low-dose or placebo group. Time to drop-out was significantly longer in the high-dose group compared to the 2 other groups. Craving scores also seemed to support the effectiveness of sustained-release naltrexone, as scorings on "needing heroin", but not on "wanting heroin", were significantly lower in the groups receiving naltrexone depot. Urinalysis findings on heroin use were reported and indicated a considerable reduction in the high-dose group compared to the low-dose or placebo group. Since urinalysis findings could not be related to number of urin samples provided per participant, these data were omitted from our analyes and calculation of overall effect estimates was considered inappropriate. Despite consistent findings, we find it premature to conclude with the effectiveness of sustained-release naltrexone for treatment of opioid dependence on the basis of only one report. Any conclusion from a systematic literature review should be based on findings from several (at least two) clinical trials using satisfactory measures to limit possible bias. One of the major challenges in oral naltrexone treatment has been high drop out rates, which are also reflected by the findings from the Cochrane review on oral naltrexone (Minozzi 2006) . When comparing oral naltrexone with or without psychosocial support to placebo, two months retention rates did not exceed 60% (Lerner 1992). The mean retention rate from the five included trials was as low as 33.3%. The two months retention rate of 68.2 % achieved in the high-dose depot group investigated by Comer 2006, indicates a considerable advantage of sustained-release naltrexone, which needs to be confirmed by further investigations. For treatment of opioid dependence, only the Russian Federation has recently approved the naltrexone implant Prodetoxone (Krupitsky 2007). However, our literature search did not retrieve any clinical trials on that formulation. Although to date evidence on effectiveness of sustained-release naltrexone for treatment of opioid dependence is clearly lacking, we would like to point out that several thousand opioid dependent patients are treated with naltrexone depots, and more frequently, implants. (Brewer 2002) and Russia (Ramenskaya 2005), naltrexone implants are used in clinical studies and, probably more widely, in private clinic settings. Independent of the circumstances of treatment, randomisedcontrolled trials seem to be the exception rather than the rule. Analysing reasons for the imbalance between number of opioid dependent patients in naltrexone implant treatment and number of good quality reports goes beyond the scope of this review.
The second objective of this systematic review was to assess the safety of sustained-release naltrexone when used in opioid and alcohol dependent samples and healthy volunteers. Safety outcomes were assessed separately for the three different populations. From a clinical perspective, qualitatively similar adverse effects would be expected regardless of treatment condition, but frequency of reporting may differ considerably due to different treatment goals in opioid (blocking the effect) and alcohol (reducing craving) dependence. Therefore, performing meta-analyses was regarded inappropriate. Nevertheless, alcohol dependent samples may contribute substantially to safety evaluation by illustrating trends applicable to opioid dependent samples.
Possibly naltrexone-related adverse effects Findings on supposedly naltrexone-related adverse effects revealed significant group differences for nausea, fatigue, vomiting, decreased appetite, dizziness and upper abdominal pain in alcohol dependent patients (Garbutt 2005; Kranzler 2004 , data not shown). These adverse effects seemed to occur in a dose-related fashion and most infrequently in the placebo group. Findings are consistent with side effects of oral naltrexone treatment described earlier (Martin 1973) . For an opioid dependent sample, Comer 2006 reports adverse effects with the most prominent symptoms being general disorders such as fatigue and administration site-related conditions. The composite outcome one or more adverse effect did not reach statistical significance, but was less frequently reported in the placebo group. These findings are in line with the Cochrane review on oral naltrexone (Minozzi 2006) . Although the number of possibly naltrexone-related adverse effects was not significantly different between groups in any RCT, the placebo groups reported adverse effects less frequently, independent of the condition studied. Severe adverse events, as reported by Garbutt 2005, were mostly hospital admissions for alcohol detoxification and favoured the naltrexone depot group. Six of ten opioid dependent participants in Waal 2003 complained about dysphoria, but this trial lacks a control group. In another trial without a control group (Waal 2006), complaints about adverse effects possibly caused by naltrexone (e.g. irritability, headache, nausea) were decreasing during the course of the study.
Administration site-related adverse effects and mortality Findings for administration site-related adverse effects showed no significant group differences for injection site pain, -induration, or -contusion. In the report by Kranzler 2004 the naltrexone depot group reported more frequently than the placebo group one or more injection site reaction. Moreover, the composite outcome any injection site-related adverse effect showed a statistically significant advantage of the placebo group compared to low-dose naltrexone in alcohol dependent samples (Garbutt 2005; Kranzler 1998; Kranzler 2004) . In the seven reports on naltrexone implant for treatment of opioid dependence, adverse effect assessment consisted of wound infection, allergic reaction to foreign body and number of implants removed. However, findings should be interpreted with caution, as the majority of the trials did not have a control group. Besides, systematic assessment of adverse effects was mostly lacking and loss to follow-up was not always reported completely. We therefore find it inappropriate to calculate prevalence of allergic reactions or wound infections. Nevertheless, it should be kept in mind that these adverse effects do occur with any of the implant formula-tions investigated and that they may lead to surgical revision of the implant site. The non-randomised trial which investigated mortality had several limitations and causality to interpret group differences cannot be imputed (Tait 2007) . Data is based on retrospective record-linkage and information on number and duration of treatment episodes was unavailable for both groups.
When gathering data on adverse effects, substantial differences in methodological quality became obvious (Table 01) . Four of the six reports on alcohol dependent patients were double-blind, placebocontrolled, randomised trials providing complete information on participants lost to follow-up. Only one out of ten reports on opioid dependent patients met a similar standard. Systematic assessment of drug-and administration site-related adverse effects was more prevalent in research involving alcohol dependent subjects compared to opioid dependent subjects. Regardless of the condition studied, any trial on experimental treatment such as sustained-release naltrexone, should be subject to the same quality requirements, i.e. active assessment and log of adverse effects, events and severe adverse events.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
To date, there is insufficient evidence to evaluate effectiveness of sustained-release naltrexone for treatment of opioid dependence. Sustained-release naltrexone formulations should still be considered investigational drugs, however, naltrexone depot injections available today seem promising in the treatment of opioid dependence. Findings of possibly sustained-release naltrexone-related side effects are in line with research on naltrexone tablets. For naltrexone depot injections, administration site-related adverse effects such as pain appear to be frequent, but usually of moderate intensity and time limited. Data on administration site-related adverse effects of naltrexone implants is scarce. Hence, commercial use of any implant formulation still needs to be evaluated thoroughly.
Implications for research
Future studies of sustained-release naltrexone involving opioid dependent patients should provide a complete description of dropout and be conducted with a control group, preferably in a randomised-controlled fashion. RCTs evaluating effectiveness for treatment of opioid dependence should compare sustained-release naltrexone to oral naltrexone or agonist replacement treatment with methadone or buprenorphine. Besides effectiveness, any research on naltrexone implants should also focus on safety to make an analysis of harm-benefit possible.
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